Skip to main
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf Inc. has demonstrated robust growth, with a notable 20% year-over-year increase in product revenues within the Banking segment, which constitutes a significant portion of its revenue. The company's order entry for 2025 has risen approximately 17% year-over-year, reflecting strong demand across both the banking and retail sectors and indicating momentum that extends into early 2026. Additionally, the transition to consistently positive free cash flow, evidenced by a 5.4% year-over-year increase in fourth-quarter free cash flow to $196 million, positions the company favorably for sustained financial improvement going forward.

Bears say

Diebold Nixdorf Inc. faces a negative outlook due to a projected decline in backlog, anticipated seasonal revenue decreases in CQ1, and ongoing risks related to tariff costs and supply chain disruptions. The company's recent financial results showed modestly missed revenue targets while experiencing a decline in backlog from $980M to $920M, raising concerns about order volatility and upgrade activity within its Banking segment. Additionally, challenges such as foreign exchange volatility, liquidity issues, and inefficiencies in product shipments exacerbate the uncertainty surrounding future cash flow generation and financial stability.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.